title: CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era.
abstract: BACKGROUND
  Studies based on seroconverters have increased our understanding of HIV disease. It is not clear, however, whether their disease progression differs from that of the general HIV population, given their reasons for presenting for testing.
  
  
  METHODS
  Using linear mixed models we compared CD4 decline rates for a seroconverter (CASCADE) and seroprevalent group (Concorde trial) with time origin being dates of seroconversion and randomization, respectively. Follow-up was censored at the earlier of last alive date and 1 January 1996. Analyses were adjusted for risk group, age and sex. To explore the role of symptomatic seroconversion we further categorized seroconverters into two groups: with and without an HIV test interval below 30 days as proxy.
  
  
  RESULTS
  The 7226 seroconverter and 1746 seroprevalent eligible individuals were mainly men (78 and 85%, respectively) infected through sex between men (52 and 63%) with mean [95% confidence interval (CI)] baseline CD4 cell count of 610 (602, 619) and 492 (479, 505) cells/μl, respectively. There was no evidence that rate of CD4 decline differs between the two groups even after adjusting for potential confounders (P = 0.67). Estimated loss in the year after reaching an arbitrary threshold of 400 cells/μl was 67 (95% CI 65, 69) and 67 (64, 69) cells/μl in the seroconverter and seroprevalent group, respectively. Whereas seroconverters with test interval below 30 days (n = 310) experienced faster decline, there was no difference in rates between other seroconverters and seroprevalent individuals (P = 0.87).
  
  
  CONCLUSIONS
  These data suggest that estimates of HIV progression derived from seroconverters are likely to hold more generally for the HIV-infected population.
authors.affiliation: MRC Clinical Trials Unit, London, UK. sal@ctu.mrc.ac.uk
authors.forename: Sara
authors.initials: S
authors.lastname: Lodi
authors.forename: Andrew
authors.initials: A
authors.lastname: Phillips
authors.forename: Giota
authors.initials: G
authors.lastname: Touloumi
authors.forename: Nikos
authors.initials: N
authors.lastname: Pantazis
authors.forename: Heiner C
authors.initials: HC
authors.lastname: Bucher
authors.forename: Abdel
authors.initials: A
authors.lastname: Babiker
authors.forename: Geneviève
authors.initials: G
authors.lastname: Chêne
authors.forename: Philippe
authors.initials: P
authors.lastname: Vanhems
authors.forename: Kholoud
authors.initials: K
authors.lastname: Porter
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D016001:Confidence Intervals; D005260:Female; D006679:HIV Seropositivity / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D008297:Male; D012307:Risk Factors; D016036:Seroepidemiologic Studies; D055815:Young Adult